Tokyo, June 1, 2019 ― FUJIFILM Corporation (President: Kenji Sukeno) will accelerate the development of next-generation cancer immunotherapeutic drug candidates by harnessing the self-renewal potential of allogenic induced pluripotent stem cells (iPSCs). FUJIFILM Cellular Dynamics, Inc. (FCDI), a leading developer and manufacturer of human iPSCs and tissue-specific cells differentiated from iPSCs, and Versant Venture Management, LLC, a leading healthcare investment firm established a new company, Century Therapeutics Inc., to start the development of next-generation cancer immunotherapies using allogeneic iPSC. Bayer AG, a global pharmaceutical company, joins the development and contribute to the development cost. [.. More ..]
